{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:23:25Z","timestamp":1790519005648,"version":"4.1.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,6,15]],"date-time":"2012-06-15T00:00:00Z","timestamp":1339718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1007\/s00018-012-1046-x","type":"journal-article","created":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T11:27:31Z","timestamp":1339673251000},"page":"259-276","source":"Crossref","is-referenced-by-count":78,"title":["Peroxisome proliferator-activated receptor-\u03b3 as a therapeutic target for hepatic fibrosis: from bench to bedside"],"prefix":"10.1007","volume":"70","author":[{"given":"Feng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,15]]},"reference":[{"key":"1046_CR1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","volume":"6","author":"V Hernandez-Gea","year":"2011","unstructured":"Hernandez-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. Annu Rev Pathol 6:425\u2013456","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"1046_CR2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2010.07.004","volume":"53","author":"D Thabut","year":"2010","unstructured":"Thabut D, Shah V (2010) Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 53(5):976\u2013980","journal-title":"J Hepatol"},{"issue":"4","key":"1046_CR3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cld.2008.07.007","volume":"12","author":"YS Lim","year":"2008","unstructured":"Lim YS, Kim WR (2008) The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 12(4):733\u2013746 vii","journal-title":"Clin Liver Dis"},{"issue":"Suppl 1","key":"1046_CR4","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S2210-7401(11)70003-1","volume":"35","author":"R Anty","year":"2011","unstructured":"Anty R, Lemoine M (2011) Liver fibrogenesis and metabolic factors. Clin Res Hepatol Gastroenterol 35(Suppl 1):S10\u2013S20","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"1046_CR5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","volume":"128","author":"M Romero-Gomez","year":"2005","unstructured":"Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, Munoz-De-Rueda P, Lopez-Serrano P, Gila A, Gutierrez ML, Perez C, Ruiz-Extremera A, Suarez E, Castillo J (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128(3):636\u2013641","journal-title":"Gastroenterology"},{"issue":"6","key":"1046_CR6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","volume":"125","author":"JM Hui","year":"2003","unstructured":"Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J (2003) Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125(6):1695\u20131704","journal-title":"Gastroenterology"},{"issue":"6","key":"1046_CR7","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.21429","volume":"44","author":"E Bugianesi","year":"2006","unstructured":"Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J (2006) Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 44(6):1648\u20131655","journal-title":"Hepatology"},{"issue":"2","key":"1046_CR8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1586\/egh.11.28","volume":"5","author":"S Minicis De","year":"2011","unstructured":"De Minicis S, Svegliati-Baroni G (2011) Fibrogenesis in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 5(2):179\u2013187","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"7\u20138","key":"1046_CR9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.addr.2009.03.011","volume":"61","author":"J Mann","year":"2009","unstructured":"Mann J, Mann DA (2009) Transcriptional regulation of hepatic stellate cells. Adv Drug Deliv Rev 61(7\u20138):497\u2013512","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"1046_CR10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.24148","volume":"53","author":"M Wagner","year":"2011","unstructured":"Wagner M, Zollner G, Trauner M (2011) Nuclear receptors in liver disease. Hepatology 53(3):1023\u20131034","journal-title":"Hepatology"},{"issue":"13","key":"1046_CR11","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.febslet.2011.05.007","volume":"585","author":"S Sugii","year":"2011","unstructured":"Sugii S, Evans RM (2011) Epigenetic codes of PPARgamma in metabolic disease. FEBS Lett 585(13):2121\u20132128","journal-title":"FEBS Lett"},{"issue":"4","key":"1046_CR12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nm1025","volume":"10","author":"RM Evans","year":"2004","unstructured":"Evans RM, Barish GD, Wang YX (2004) PPARs and the complex journey to obesity. Nat Med 10(4):355\u2013361","journal-title":"Nat Med"},{"issue":"9","key":"1046_CR13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nsmb.1474","volume":"15","author":"T Itoh","year":"2008","unstructured":"Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K, Schwabe JW (2008) Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat Struct Mol Biol 15(9):924\u2013931","journal-title":"Nat Struct Mol Biol"},{"issue":"8","key":"1046_CR14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.tem.2006.08.005","volume":"17","author":"G Pascual","year":"2006","unstructured":"Pascual G, Glass CK (2006) Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 17(8):321\u2013327","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"1046_CR15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4049\/jimmunol.181.1.235","volume":"181","author":"TL Bonfield","year":"2008","unstructured":"Bonfield TL, Thomassen MJ, Farver CF, Abraham S, Koloze MT, Zhang X, Mosser DM, Culver DA (2008) Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor. J Immunol 181(1):235\u2013242","journal-title":"J Immunol"},{"issue":"4","key":"1046_CR16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/vim.2010.0016","volume":"23","author":"J Bassaganya-Riera","year":"2010","unstructured":"Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R (2010) PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol 23(4):343\u2013352","journal-title":"Viral Immunol"},{"issue":"3","key":"1046_CR17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1677\/JME-10-0007","volume":"45","author":"S Suzuki","year":"2010","unstructured":"Suzuki S, Sasaki S, Morita H, Oki Y, Turiya D, Ito T, Misawa H, Ishizuka K, Nakamura H (2010) The role of the amino-terminal domain in the interaction of unliganded peroxisome proliferator-activated receptor gamma-2 with nuclear receptor co-repressor. J Mol Endocrinol 45(3):133\u2013145","journal-title":"J Mol Endocrinol"},{"issue":"6","key":"1046_CR18","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1074\/jbc.M108473200","volume":"277","author":"ZE Floyd","year":"2002","unstructured":"Floyd ZE, Stephens JM (2002) Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J Biol Chem 277(6):4062\u20134068","journal-title":"J Biol Chem"},{"issue":"2","key":"1046_CR19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nm1706","volume":"14","author":"T Hosooka","year":"2008","unstructured":"Hosooka T, Noguchi T, Kotani K, Nakamura T, Sakaue H, Inoue H, Ogawa W, Tobimatsu K, Takazawa K, Sakai M, Matsuki Y, Hiramatsu R, Yasuda T, Lazar MA, Yamanashi Y, Kasuga M (2008) Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation. Nat Med 14(2):188\u2013193","journal-title":"Nat Med"},{"issue":"4","key":"1046_CR20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/13543781003640169","volume":"19","author":"LS Doshi","year":"2010","unstructured":"Doshi LS, Brahma MK, Bahirat UA, Dixit AV, Nemmani KV (2010) Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. Expert Opin Investig Drugs 19(4):489\u2013512","journal-title":"Expert Opin Investig Drugs"},{"issue":"3\u20134","key":"1046_CR21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.reprotox.2008.10.001","volume":"27","author":"BD Abbott","year":"2009","unstructured":"Abbott BD (2009) Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol 27(3\u20134):246\u2013257","journal-title":"Reprod Toxicol"},{"issue":"3","key":"1046_CR22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1172\/JCI28003","volume":"116","author":"RK Semple","year":"2006","unstructured":"Semple RK, Chatterjee VK, O\u2019Rahilly S (2006) PPAR gamma and human metabolic disease. J Clin Invest 116(3):581\u2013589","journal-title":"J Clin Invest"},{"issue":"7","key":"1046_CR23","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bjp.2008.21","volume":"153","author":"GH Hao","year":"2008","unstructured":"Hao GH, Niu XL, Gao DF, Wei J, Wang NP (2008) Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts. Br J Pharmacol 153(7):1409\u20131419","journal-title":"Br J Pharmacol"},{"issue":"2\u20133","key":"1046_CR24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.vph.2009.06.004","volume":"51","author":"Y Ren","year":"2009","unstructured":"Ren Y, Sun C, Sun Y, Tan H, Wu Y, Cui B, Wu Z (2009) PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul Pharmacol 51(2\u20133):169\u2013174","journal-title":"Vascul Pharmacol"},{"issue":"4","key":"1046_CR25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1189\/jlb.71.4.677","volume":"71","author":"DG Alleva","year":"2002","unstructured":"Alleva DG, Johnson EB, Lio FM, Boehme SA, Conlon PJ, Crowe PD (2002) Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma. J Leukoc Biol 71(4):677\u2013685","journal-title":"J Leukoc Biol"},{"issue":"2","key":"1046_CR26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cmet.2007.06.010","volume":"6","author":"MA Bouhlel","year":"2007","unstructured":"Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G (2007) PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6(2):137\u2013143","journal-title":"Cell Metab"},{"issue":"1","key":"1046_CR27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2796.2007.01892.x","volume":"263","author":"MA Bouhlel","year":"2008","unstructured":"Bouhlel MA, Staels B, Chinetti-Gbaguidi G (2008) Peroxisome proliferator-activated receptors\u2014from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. J Intern Med 263(1):28\u201342","journal-title":"J Intern Med"},{"issue":"5","key":"1046_CR28","doi-asserted-by":"crossref","first-page":"L891","DOI":"10.1152\/ajplung.00333.2007","volume":"294","author":"JE Milam","year":"2008","unstructured":"Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, Hogaboam CM, Standiford TJ, Thannickal VJ, Reddy RC (2008) PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294(5):L891\u2013L901","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"1046_CR29","first-page":"157","volume":"30","author":"S Dionne","year":"2010","unstructured":"Dionne S, Levy E, Levesque D, Seidman EG (2010) PPARgamma ligand 15-deoxy-delta 12,14-prostaglandin J2 sensitizes human colon carcinoma cells to TWEAK-induced apoptosis. Anticancer Res 30(1):157\u2013166","journal-title":"Anticancer Res"},{"issue":"4","key":"1046_CR30","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.cell.2006.06.050","volume":"126","author":"X Yang","year":"2006","unstructured":"Yang X, Downes M, Yu RT, Bookout AL, He W, Straume M, Mangelsdorf DJ, Evans RM (2006) Nuclear receptor expression links the circadian clock to metabolism. Cell 126(4):801\u2013810","journal-title":"Cell"},{"issue":"3","key":"1046_CR31","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/jcp.20804","volume":"209","author":"S Botolin","year":"2006","unstructured":"Botolin S, McCabe LR (2006) Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol 209(3):967\u2013976","journal-title":"J Cell Physiol"},{"issue":"3","key":"1046_CR32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/s-0030-1255351","volume":"30","author":"HE Wasmuth","year":"2010","unstructured":"Wasmuth HE, Tacke F, Trautwein C (2010) Chemokines in liver inflammation and fibrosis. Semin Liver Dis 30(3):215\u2013225","journal-title":"Semin Liver Dis"},{"issue":"2","key":"1046_CR33","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/ar.a.20230","volume":"286","author":"N Higashi","year":"2005","unstructured":"Higashi N, Sato M, Kojima N, Irie T, Kawamura K, Mabuchi A, Senoo H (2005) Vitamin A storage in hepatic stellate cells in the regenerating rat liver: with special reference to zonal heterogeneity. Anat Rec A Discov Mol Cell Evol Biol 286(2):899\u2013907","journal-title":"Anat Rec A Discov Mol Cell Evol Biol"},{"issue":"1","key":"1046_CR34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","volume":"88","author":"SL Friedman","year":"2008","unstructured":"Friedman SL (2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88(1):125\u2013172","journal-title":"Physiol Rev"},{"issue":"46","key":"1046_CR35","doi-asserted-by":"crossref","first-page":"35715","DOI":"10.1074\/jbc.M006577200","volume":"275","author":"T Miyahara","year":"2000","unstructured":"Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, Anania FA, Willson TM, Tsukamoto H (2000) Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275(46):35715\u201335722","journal-title":"J Biol Chem"},{"issue":"6","key":"1046_CR36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1745-7254.2006.00299.x","volume":"27","author":"K Sun","year":"2006","unstructured":"Sun K, Wang Q, Huang XH (2006) PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol Sin 27(6):715\u2013723","journal-title":"Acta Pharmacol Sin"},{"issue":"47","key":"1046_CR37","doi-asserted-by":"crossref","first-page":"36361","DOI":"10.1074\/jbc.M110.137661","volume":"285","author":"Y Higashi","year":"2010","unstructured":"Higashi Y, Holder K, Delafontaine P (2010) Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway. J Biol Chem 285(47):36361\u201336368","journal-title":"J Biol Chem"},{"issue":"12","key":"1046_CR38","doi-asserted-by":"crossref","first-page":"11392","DOI":"10.1074\/jbc.M310284200","volume":"279","author":"S Hazra","year":"2004","unstructured":"Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, Tsukamoto H (2004) Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 279(12):11392\u201311401","journal-title":"J Biol Chem"},{"issue":"7","key":"1046_CR39","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/gast.2002.33666","volume":"122","author":"A Galli","year":"2002","unstructured":"Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C, Casini A (2002) Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 122(7):1924\u20131940","journal-title":"Gastroenterology"},{"issue":"49","key":"1046_CR40","doi-asserted-by":"crossref","first-page":"40650","DOI":"10.1074\/jbc.M510094200","volume":"280","author":"S Yavrom","year":"2005","unstructured":"Yavrom S, Chen L, Xiong S, Wang J, Rippe RA, Tsukamoto H (2005) Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells. J Biol Chem 280(49):40650\u201340659","journal-title":"J Biol Chem"},{"issue":"1","key":"1046_CR41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/jpet.105.085597","volume":"315","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Morelli A, Pruzanski M, Pellicciari R (2005) Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 315(1):58\u201368","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1046_CR42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00011-010-0306-1","volume":"60","author":"B Renga","year":"2011","unstructured":"Renga B, Mencarelli A, Migliorati M, Cipriani S, D\u2019Amore C, Distrutti E, Fiorucci S (2011) SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-gamma by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts. Inflamm Res 60(6):577\u2013587","journal-title":"Inflamm Res"},{"issue":"5","key":"1046_CR43","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","volume":"127","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pellicciari R, Morelli A (2004) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127(5):1497\u20131512","journal-title":"Gastroenterology"},{"issue":"2","key":"1046_CR44","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","volume":"314","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pruzanski M, Morelli A, Pellicciari R (2005) A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 314(2):584\u2013595","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1046_CR45","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","volume":"175","author":"P Fickert","year":"2009","unstructured":"Fickert P, Fuchsbichler A, Moustafa T, Wagner M, Zollner G, Halilbasic E, Stoger U, Arrese M, Pizarro M, Solis N, Carrasco G, Caligiuri A, Sombetzki M, Reisinger E, Tsybrovskyy O, Zatloukal K, Denk H, Jaeschke H, Pinzani M, Trauner M (2009) Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 175(6):2392\u20132405","journal-title":"Am J Pathol"},{"issue":"3","key":"1046_CR46","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s13105-011-0101-7","volume":"67","author":"P Sauvant","year":"2011","unstructured":"Sauvant P, Cansell M, Atgie C (2011) Vitamin A and lipid metabolism: relationship between hepatic stellate cells (HSCs) and adipocytes. J Physiol Biochem 67(3):487\u2013496","journal-title":"J Physiol Biochem"},{"issue":"Suppl 3","key":"1046_CR47","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1111\/j.1440-1746.2006.04573.x","volume":"21","author":"H Tsukamoto","year":"2006","unstructured":"Tsukamoto H, She H, Hazra S, Cheng J, Miyahara T (2006) Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. J Gastroenterol Hepatol 21(Suppl 3):S102\u2013S105","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"1046_CR48","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1053\/j.gastro.2007.02.033","volume":"132","author":"S Minicis De","year":"2007","unstructured":"De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, Schwabe RF (2007) Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 132(5):1937\u20131946","journal-title":"Gastroenterology"},{"issue":"6","key":"1046_CR49","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1074\/jbc.M410078200","volume":"280","author":"H She","year":"2005","unstructured":"She H, Xiong S, Hazra S, Tsukamoto H (2005) Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 280(6):4959\u20134967","journal-title":"J Biol Chem"},{"issue":"9","key":"1046_CR50","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1478-3231.2007.01578.x","volume":"27","author":"EL Guimaraes","year":"2007","unstructured":"Guimaraes EL, Franceschi MF, Andrade CM, Guaragna RM, Borojevic R, Margis R, Bernard EA, Guma FC (2007) Hepatic stellate cell line modulates lipogenic transcription factors. Liver Int 27(9):1255\u20131264","journal-title":"Liver Int"},{"issue":"1","key":"1046_CR51","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bbrc.2009.11.112","volume":"391","author":"N Kim","year":"2010","unstructured":"Kim N, Choi S, Lim C, Lee H, Oh J (2010) Albumin mediates PPAR-gamma or C\/EBP-alpha-induced phenotypic changes in pancreatic stellate cells. Biochem Biophys Res Commun 391(1):640\u2013644","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1046_CR52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0168-8278(01)00066-6","volume":"35","author":"M Bedoucha","year":"2001","unstructured":"Bedoucha M, Atzpodien E, Boelsterli UA (2001) Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 35(1):17\u201323","journal-title":"J Hepatol"},{"issue":"1","key":"1046_CR53","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1074\/jbc.M210062200","volume":"278","author":"S Yu","year":"2003","unstructured":"Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ, Reddy JK (2003) Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 278(1):498\u2013505","journal-title":"J Biol Chem"},{"issue":"4","key":"1046_CR54","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2302\/kjm.54.190","volume":"54","author":"H Tsukamoto","year":"2005","unstructured":"Tsukamoto H (2005) Fat paradox in liver disease. Keio J Med 54(4):190\u2013192","journal-title":"Keio J Med"},{"issue":"9","key":"1046_CR55","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1136\/gut.2010.209551","volume":"60","author":"J Kluwe","year":"2011","unstructured":"Kluwe J, Wongsiriroj N, Troeger JS, Gwak GY, Dapito DH, Pradere JP, Jiang H, Siddiqi M, Piantedosi R, O\u2019Byrne SM, Blaner WS, Schwabe RF (2011) Absence of hepatic stellate cell retinoid lipid droplets does not enhance hepatic fibrosis but decreases hepatic carcinogenesis. Gut 60(9):1260\u20131268","journal-title":"Gut"},{"issue":"2","key":"1046_CR56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.cdd.4401979","volume":"14","author":"J Mann","year":"2007","unstructured":"Mann J, Oakley F, Akiboye F, Elsharkawy A, Thorne AW, Mann DA (2007) Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ 14(2):275\u2013285","journal-title":"Cell Death Differ"},{"issue":"2","key":"1046_CR57","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1053\/j.gastro.2009.10.002","volume":"138","author":"J Mann","year":"2010","unstructured":"Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, Mann DA (2010) MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 138(2):705\u2013714","journal-title":"Gastroenterology"},{"issue":"40","key":"1046_CR58","doi-asserted-by":"crossref","first-page":"30463","DOI":"10.1074\/jbc.M110.156703","volume":"285","author":"NL Zhu","year":"2010","unstructured":"Zhu NL, Wang J, Tsukamoto H (2010) The Necdin-Wnt pathway causes epigenetic peroxisome proliferator-activated receptor gamma repression in hepatic stellate cells. J Biol Chem 285(40):30463\u201330471","journal-title":"J Biol Chem"},{"issue":"13","key":"1046_CR59","doi-asserted-by":"crossref","first-page":"10355","DOI":"10.1074\/jbc.M111.312751","volume":"287","author":"NL Zhu","year":"2012","unstructured":"Zhu NL, Asahina K, Wang J, Ueno A, Lazaro R, Miyaoka Y, Miyajima A, Tsukamoto H (2012) Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration. J Biol Chem 287(13):10355\u201310367","journal-title":"J Biol Chem"},{"issue":"48","key":"1046_CR60","doi-asserted-by":"crossref","first-page":"31751","DOI":"10.1074\/jbc.273.48.31751","volume":"273","author":"CM Smas","year":"1998","unstructured":"Smas CM, Kachinskas D, Liu CM, Xie X, Dircks LK, Sul HS (1998) Transcriptional control of the pref-1 gene in 3T3-L1 adipocyte differentiation. Sequence requirement for differentiation-dependent suppression. J Biol Chem 273(48):31751\u201331758","journal-title":"J Biol Chem"},{"issue":"3","key":"1046_CR61","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jmb.2007.06.006","volume":"371","author":"D Fritz","year":"2007","unstructured":"Fritz D, Stefanovic B (2007) RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1. J Mol Biol 371(3):585\u2013595","journal-title":"J Mol Biol"},{"issue":"1","key":"1046_CR62","doi-asserted-by":"crossref","first-page":"G101","DOI":"10.1152\/ajpgi.00220.2009","volume":"298","author":"SK Venugopal","year":"2010","unstructured":"Venugopal SK, Jiang J, Kim TH, Li Y, Wang SS, Torok NJ, Wu J, Zern MA (2010) Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol 298(1):G101\u2013G106","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"22","key":"1046_CR63","doi-asserted-by":"crossref","first-page":"23822","DOI":"10.1074\/jbc.M314060200","volume":"279","author":"JN Lindquist","year":"2004","unstructured":"Lindquist JN, Parsons CJ, Stefanovic B, Brenner DA (2004) Regulation of alpha1(I) collagen messenger RNA decay by interactions with alphaCP at the 3\u2032-untranslated region. J Biol Chem 279(22):23822\u201323829","journal-title":"J Biol Chem"},{"issue":"4","key":"1046_CR64","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/hep.24792","volume":"55","author":"MD Yang","year":"2012","unstructured":"Yang MD, Chiang YM, Higashiyama R, Asahina K, Mann DA, Mann J, Wang CC, Tsukamoto H (2012) Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor gamma in hepatic stellate cells for their antifibrotic effect. Hepatology 55(4):1271\u20131281","journal-title":"Hepatology"},{"issue":"5","key":"1046_CR65","doi-asserted-by":"crossref","first-page":"G902","DOI":"10.1152\/ajpgi.00124.2006","volume":"291","author":"L Yang","year":"2006","unstructured":"Yang L, Chan CC, Kwon OS, Liu S, McGhee J, Stimpson SA, Chen LZ, Harrington WW, Symonds WT, Rockey DC (2006) Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 291(5):G902\u2013G911","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"1046_CR66","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/gt.2010.41","volume":"17","author":"CW Wu","year":"2010","unstructured":"Wu CW, Chu ES, Lam CN, Cheng AS, Lee CW, Wong VW, Sung JJ, Yu J (2010) PPARgamma is essential for protection against nonalcoholic steatohepatitis. Gene Ther 17(6):790\u2013798","journal-title":"Gene Ther"},{"issue":"6","key":"1046_CR67","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.biocel.2010.02.006","volume":"42","author":"J Yu","year":"2010","unstructured":"Yu J, Zhang S, Chu ES, Go MY, Lau RH, Zhao J, Wu CW, Tong L, Poon TC, Sung JJ (2010) Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro. Int J Biochem Cell Biol 42(6):948\u2013957","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"1046_CR68","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3109\/00365521.2010.525717","volume":"46","author":"YM Nan","year":"2011","unstructured":"Nan YM, Han F, Kong LB, Zhao SX, Wang RQ, Wu WJ, Yu J (2011) Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand J Gastroenterol 46(3):358\u2013369","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"1046_CR69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1499-3872(11)60009-X","volume":"10","author":"Z Wang","year":"2011","unstructured":"Wang Z, Xu JP, Zheng YC, Chen W, Sun YW, Wu ZY, Luo M (2011) Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats. Hepatobiliary Pancreat Dis Int 10(1):64\u201371","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"5","key":"1046_CR70","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/17425240902936834","volume":"6","author":"F Li","year":"2009","unstructured":"Li F, Wang JY (2009) Targeted delivery of drugs for liver fibrosis. Expert Opin Drug Deliv 6(5):531\u2013541","journal-title":"Expert Opin Drug Deliv"},{"issue":"22","key":"1046_CR71","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270(22):12953\u201312956","journal-title":"J Biol Chem"},{"issue":"6","key":"1046_CR72","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/pds.652","volume":"10","author":"GA Faich","year":"2001","unstructured":"Faich GA, Moseley RH (2001) Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf 10(6):537\u2013547","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1046_CR73","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/gast.2000.9365","volume":"119","author":"F Marra","year":"2000","unstructured":"Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P (2000) Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119(2):466\u2013478","journal-title":"Gastroenterology"},{"issue":"32","key":"1046_CR74","first-page":"4931","volume":"11","author":"F Marra","year":"2005","unstructured":"Marra F, DeFranco R, Robino G, Novo E, Efsen E, Pastacaldi S, Zamara E, Vercelli A, Lottini B, Spirli C, Strazzabosco M, Pinzani M, Parola M (2005) Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J Gastroenterol 11(32):4931\u20134938","journal-title":"World J Gastroenterol"},{"issue":"32","key":"1046_CR75","doi-asserted-by":"crossref","first-page":"23337","DOI":"10.1074\/jbc.M700194200","volume":"282","author":"M Zeisberg","year":"2007","unstructured":"Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, Kalluri R (2007) Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282(32):23337\u201323347","journal-title":"J Biol Chem"},{"issue":"10","key":"1046_CR76","first-page":"3331","volume":"118","author":"A Omenetti","year":"2008","unstructured":"Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, Choi SS, Witek RP, Alpini G, Venter J, Vandongen HM, Syn WK, Baroni GS, Benedetti A, Schuppan D, Diehl AM (2008) Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 118(10):3331\u20133342","journal-title":"J Clin Invest"},{"issue":"3","key":"1046_CR77","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/hep.23368","volume":"51","author":"K Taura","year":"2010","unstructured":"Taura K, Miura K, Iwaisako K, Osterreicher CH, Kodama Y, Penz-Osterreicher M, Brenner DA (2010) Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 51(3):1027\u20131036","journal-title":"Hepatology"},{"issue":"3","key":"1046_CR78","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.gastro.2010.05.005","volume":"139","author":"D Scholten","year":"2010","unstructured":"Scholten D, Osterreicher CH, Scholten A, Iwaisako K, Gu G, Brenner DA, Kisseleva T (2010) Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 139(3):987\u2013998","journal-title":"Gastroenterology"},{"issue":"5","key":"1046_CR79","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/hep.24206","volume":"53","author":"AS Chu","year":"2011","unstructured":"Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, Stanger BZ, Wells RG (2011) Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 53(5):1685\u20131695","journal-title":"Hepatology"},{"issue":"12","key":"1046_CR80","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s10620-007-9756-x","volume":"52","author":"V Tahan","year":"2007","unstructured":"Tahan V, Eren F, Avsar E, Yavuz D, Yuksel M, Emekli E, Imeryuz N, Celikel C, Uzun H, Haklar G, Tozun N (2007) Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. Dig Dis Sci 52(12):3465\u20133472","journal-title":"Dig Dis Sci"},{"issue":"18","key":"1046_CR81","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3748\/wjg.14.2905","volume":"14","author":"H Chen","year":"2008","unstructured":"Chen H, He YW, Liu WQ, Zhang JH (2008) Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum. World J Gastroenterol 14(18):2905\u20132911","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1046_CR82","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/00365520802530861","volume":"44","author":"YM Nan","year":"2009","unstructured":"Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM, Yu J (2009) Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol 44(3):358\u2013365","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"1046_CR83","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23941","volume":"52","author":"AA Gupte","year":"2010","unstructured":"Gupte AA, Liu JZ, Ren Y, Minze LJ, Wiles JR, Collins AR, Lyon CJ, Pratico D, Finegold MJ, Wong ST, Webb P, Baxter JD, Moore DD, Hsueh WA (2010) Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology 52(6):2001\u20132011","journal-title":"Hepatology"},{"issue":"2","key":"1046_CR84","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s10620-008-0336-5","volume":"54","author":"R Bruck","year":"2009","unstructured":"Bruck R, Weiss S, Aeed H, Pines M, Halpern Z, Zvibel I (2009) Additive inhibitory effect of experimentally induced hepatic cirrhosis by agonists of peroxisome proliferator activator receptor gamma and retinoic acid receptor. Dig Dis Sci 54(2):292\u2013299","journal-title":"Dig Dis Sci"},{"issue":"3","key":"1046_CR85","doi-asserted-by":"crossref","first-page":"G364","DOI":"10.1152\/ajpgi.00456.2009","volume":"298","author":"Z Shen","year":"2010","unstructured":"Shen Z, Liang X, Rogers CQ, Rideout D, You M (2010) Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 298(3):G364\u2013G374","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"1046_CR86","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.21687","volume":"46","author":"I Garcia-Ruiz","year":"2007","unstructured":"Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, Martinez MA, Munoz-Yague T, Solis-Herruzo JA (2007) Effects of rosiglitazone on the liver histology and mitochondrial function in ob\/ob mice. Hepatology 46(2):414\u2013423","journal-title":"Hepatology"},{"issue":"1","key":"1046_CR87","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/bbrc.2002.6385","volume":"291","author":"K Kon","year":"2002","unstructured":"Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, Takei Y, Sato N (2002) Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 291(1):55\u201361","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"1046_CR88","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3748\/wjg.v10.i7.1047","volume":"10","author":"GJ Yuan","year":"2004","unstructured":"Yuan GJ, Zhang ML, Gong ZJ (2004) Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World J Gastroenterol 10(7):1047\u20131051","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1046_CR89","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1124\/jpet.102.047217","volume":"306","author":"N Enomoto","year":"2003","unstructured":"Enomoto N, Takei Y, Hirose M, Konno A, Shibuya T, Matsuyama S, Suzuki S, Kitamura KI, Sato N (2003) Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J Pharmacol Exp Ther 306(3):846\u2013854","journal-title":"J Pharmacol Exp Ther"},{"issue":"12 Suppl","key":"1046_CR90","doi-asserted-by":"crossref","first-page":"216S","DOI":"10.1097\/01.alc.0000192394.26573.10","volume":"29","author":"N Enomoto","year":"2005","unstructured":"Enomoto N, Takei Y, Yamashima S, Ikejima K, Kitamura T, Sato N (2005) Protective effect of pioglitazone against endotoxin-induced liver injury through prevention of Kupffer cell sensitization. Alcohol Clin Exp Res 29(12 Suppl):216S\u2013219S","journal-title":"Alcohol Clin Exp Res"},{"key":"1046_CR91","doi-asserted-by":"crossref","unstructured":"Ohata M, Suzuki H, Sakamoto K, Hashimoto K, Nakajima H, Yamauchi M, Hokkyo K, Yamada H, Toda G (2004) Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha. Alcohol Clin Exp Res 28(8 Suppl Proceedings):139S\u2013144S","DOI":"10.1097\/01.ALC.0000134412.38510.F7"},{"issue":"3","key":"1046_CR92","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/j.gastro.2003.12.008","volume":"126","author":"K Tomita","year":"2004","unstructured":"Tomita K, Azuma T, Kitamura N, Nishida J, Tamiya G, Oka A, Inokuchi S, Nishimura T, Suematsu M, Ishii H (2004) Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 126(3):873\u2013885","journal-title":"Gastroenterology"},{"issue":"1","key":"1046_CR93","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2004.01.038","volume":"315","author":"K Kawaguchi","year":"2004","unstructured":"Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K (2004) Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined diet. Biochem Biophys Res Commun 315(1):187\u2013195","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1046_CR94","first-page":"235","volume":"32","author":"H Uto","year":"2005","unstructured":"Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H, Numata M, Nagata K, Hayashi K, Tsubouchi H (2005) The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet. Hepatol Res 32(4):235\u2013242","journal-title":"Hepatol Res"},{"issue":"8","key":"1046_CR95","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1111\/j.1476-5381.2010.00671.x","volume":"160","author":"M Collino","year":"2010","unstructured":"Collino M, Aragno M, Castiglia S, Miglio G, Tomasinelli C, Boccuzzi G, Thiemermann C, Fantozzi R (2010) Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol 160(8):1892\u20131902","journal-title":"Br J Pharmacol"},{"issue":"7","key":"1046_CR96","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/gut.2005.079194","volume":"55","author":"IA Leclercq","year":"2006","unstructured":"Leclercq IA, Sempoux C, Starkel P, Horsmans Y (2006) Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats. Gut 55(7):1020\u20131029","journal-title":"Gut"},{"issue":"1","key":"1046_CR97","first-page":"105","volume":"19","author":"Morais A Silva Da","year":"2007","unstructured":"Da Silva Morais A, Abarca-Quinones J, Horsmans Y, Starkel P, Leclercq IA (2007) Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice. Int J Mol Med 19(1):105\u2013112","journal-title":"Int J Mol Med"},{"issue":"3","key":"1046_CR98","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12272-010-0313-3","volume":"33","author":"MA Bae","year":"2010","unstructured":"Bae MA, Rhee SD, Jung WH, Ahn JH, Song BJ, Cheon HG (2010) Selective inhibition of activated stellate cells and protection from carbon tetrachloride-induced liver injury in rats by a new PPARgamma agonist KR62776. Arch Pharm Res 33(3):433\u2013442","journal-title":"Arch Pharm Res"},{"issue":"12","key":"1046_CR99","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00011-010-0226-0","volume":"59","author":"L Yang","year":"2010","unstructured":"Yang L, Stimpson SA, Chen L, Wallace Harrington W, Rockey DC (2010) Effectiveness of the PPARgamma agonist, GW570, in liver fibrosis. Inflamm Res 59(12):1061\u20131071","journal-title":"Inflamm Res"},{"issue":"15","key":"1046_CR100","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1021\/jm060389m","volume":"49","author":"JH Ahn","year":"2006","unstructured":"Ahn JH, Shin MS, Jung SH, Kang SK, Kim KR, Rhee SD, Jung WH, Yang SD, Kim SJ, Woo JR, Lee JH, Cheon HG, Kim SS (2006) Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. J Med Chem 49(15):4781\u20134784","journal-title":"J Med Chem"},{"issue":"Pt 1","key":"1046_CR101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1042\/BJ20040928","volume":"384","author":"S Zheng","year":"2004","unstructured":"Zheng S, Chen A (2004) Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J 384(Pt 1):149\u2013157","journal-title":"Biochem J"},{"issue":"1","key":"1046_CR102","doi-asserted-by":"crossref","first-page":"G113","DOI":"10.1152\/ajpgi.00200.2006","volume":"292","author":"S Zheng","year":"2007","unstructured":"Zheng S, Chen A (2007) Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 292(1):G113\u2013G123","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"1046_CR103","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1124\/mol.107.039818","volume":"73","author":"Y Fu","year":"2008","unstructured":"Fu Y, Zheng S, Lin J, Ryerse J, Chen A (2008) Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol 73(2):399\u2013409","journal-title":"Mol Pharmacol"},{"issue":"4","key":"1046_CR104","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cld.2009.07.005","volume":"13","author":"CK Argo","year":"2009","unstructured":"Argo CK, Caldwell SH (2009) Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 13(4):511\u2013531","journal-title":"Clin Liver Dis"},{"issue":"5","key":"1046_CR105","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/hep.23594","volume":"51","author":"BQ Starley","year":"2010","unstructured":"Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51(5):1820\u20131832","journal-title":"Hepatology"},{"issue":"6037","key":"1046_CR106","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","volume":"332","author":"JC Cohen","year":"2011","unstructured":"Cohen JC, Horton JD, Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332(6037):1519\u20131523","journal-title":"Science"},{"issue":"2","key":"1046_CR107","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1572-0241.2001.03553.x","volume":"96","author":"SH Caldwell","year":"2001","unstructured":"Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL (2001) A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 96(2):519\u2013525","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1046_CR108","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/MCG.0b013e31818f4fc2","volume":"43","author":"CK Argo","year":"2009","unstructured":"Argo CK, Iezzoni JC, Al-Osaimi AM, Caldwell SH (2009) Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? J Clin Gastroenterol 43(6):565\u2013568","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"1046_CR109","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0168-8278(03)00027-8","volume":"38","author":"BA Neuschwander-Tetri","year":"2003","unstructured":"Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR (2003) Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 38(4):434\u2013440","journal-title":"J Hepatol"},{"issue":"4","key":"1046_CR110","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/jhep.2003.50420","volume":"38","author":"BA Neuschwander-Tetri","year":"2003","unstructured":"Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR (2003) Improved nonalcoholic steatohepatitis after 48\u00a0weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38(4):1008\u20131017","journal-title":"Hepatology"},{"issue":"2","key":"1046_CR111","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2036.2008.03723.x","volume":"28","author":"R Idilman","year":"2008","unstructured":"Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, Coban S, Erden E, Soykan I, Emral R, Uysal AR, Ozden A (2008) Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 28(2):200\u2013208","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1046_CR112","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/hep.21813","volume":"46","author":"SH Caldwell","year":"2007","unstructured":"Caldwell SH, Patrie JT, Brunt EM, Redick JA, Davis CA, Park SH, Neuschwander-Tetri BA (2007) The effects of 48\u00a0weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. Hepatology 46(4):1101\u20131107","journal-title":"Hepatology"},{"issue":"9","key":"1046_CR113","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0929-6646(09)60202-3","volume":"105","author":"CH Wang","year":"2006","unstructured":"Wang CH, Leung CH, Liu SC, Chung CH (2006) Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease. J Formos Med Assoc 105(9):743\u2013752","journal-title":"J Formos Med Assoc"},{"issue":"3","key":"1046_CR114","doi-asserted-by":"crossref","first-page":"61","DOI":"10.20452\/pamw.1023","volume":"121","author":"M Saryusz-Wolska","year":"2011","unstructured":"Saryusz-Wolska M, Szymanska-Garbacz E, Jablkowski M, Bialkowska J, Pawlowski M, Kwiecinska E, Omulecka A, Borkowska A, Ignaczak A, Loba J, Czupryniak L (2011) Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease. Pol Arch Med Wewn 121(3):61\u201366","journal-title":"Pol Arch Med Wewn"},{"issue":"1","key":"1046_CR115","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","volume":"135","author":"V Ratziu","year":"2008","unstructured":"Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) Trial. Gastroenterology 135(1):100\u2013110","journal-title":"Gastroenterology"},{"issue":"6","key":"1046_CR116","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313\u20131321","journal-title":"Hepatology"},{"issue":"2","key":"1046_CR117","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/hep.23270","volume":"51","author":"V Ratziu","year":"2010","unstructured":"Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, Hartmann-Heurtier A, Bruckert E, Poynard T (2010) Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51(2):445\u2013453","journal-title":"Hepatology"},{"issue":"1","key":"1046_CR118","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MEG.0b013e32832e2baf","volume":"22","author":"Z Omer","year":"2010","unstructured":"Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, Akarca U (2010) Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 22(1):18\u201323","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"1046_CR119","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.24558","volume":"54","author":"DM Torres","year":"2011","unstructured":"Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA (2011) Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology 54(5):1631\u20131639","journal-title":"Hepatology"},{"issue":"5","key":"1046_CR120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/S1542-3565(03)00198-8","volume":"1","author":"S Shadid","year":"2003","unstructured":"Shadid S, Jensen MD (2003) Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol 1(5):384\u2013387","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1046_CR121","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","volume":"39","author":"K Promrat","year":"2004","unstructured":"Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39(1):188\u2013196","journal-title":"Hepatology"},{"issue":"22","key":"1046_CR122","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355(22):2297\u20132307","journal-title":"N Engl J Med"},{"issue":"4","key":"1046_CR123","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","volume":"135","author":"GP Aithal","year":"2008","unstructured":"Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135(4):1176\u20131184","journal-title":"Gastroenterology"},{"issue":"2","key":"1046_CR124","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/hep.21661","volume":"46","author":"G Lutchman","year":"2007","unstructured":"Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, Hoofnagle JH (2007) The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46(2):424\u2013429","journal-title":"Hepatology"},{"issue":"8","key":"1046_CR125","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2006.05.005","volume":"4","author":"G Lutchman","year":"2006","unstructured":"Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, Yanovski JA, Liang TJ, Hoofnagle JH (2006) Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 4(8):1048\u20131052","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"1046_CR126","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.23116","volume":"50","author":"A Gastaldelli","year":"2009","unstructured":"Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K (2009) Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50(4):1087\u20131093","journal-title":"Hepatology"},{"key":"1046_CR127","doi-asserted-by":"crossref","unstructured":"Urtasun R, Conde de la Rosa L, Nieto N (2008) Oxidative and nitrosative stress and fibrogenic response. Clin Liver Dis 12(4):769\u2013790, viii","DOI":"10.1016\/j.cld.2008.07.005"},{"issue":"12","key":"1046_CR128","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1542-3565(04)00457-4","volume":"2","author":"AJ Sanyal","year":"2004","unstructured":"Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Clore J, Mills AS (2004) A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2(12):1107\u20131115","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1046_CR129","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cct.2008.09.003","volume":"30","author":"NP Chalasani","year":"2009","unstructured":"Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J (2009) Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 30(1):88\u201396","journal-title":"Contemp Clin Trials"},{"issue":"18","key":"1046_CR130","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362(18):1675\u20131685","journal-title":"N Engl J Med"},{"key":"1046_CR131","doi-asserted-by":"crossref","unstructured":"McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, Rockey D, Husa P, Chuang WL, Levine R, Jonas M, Theodore D, Brigandi R, Webster A, Schultz M, Watson H, Stancil B, Gardner S (2010) Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology 138(4):1365\u20131373","DOI":"10.1053\/j.gastro.2009.12.003"},{"issue":"3","key":"1046_CR132","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI30542","volume":"117","author":"JP Iredale","year":"2007","unstructured":"Iredale JP (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117(3):539\u2013548","journal-title":"J Clin Invest"},{"issue":"1","key":"1046_CR133","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.23623","volume":"52","author":"G Musso","year":"2010","unstructured":"Musso G, Gambino R, Cassader M, Pagano G (2010) A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52(1):79\u2013104","journal-title":"Hepatology"},{"issue":"6","key":"1046_CR134","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jhep.2011.03.016","volume":"55","author":"SE Mahady","year":"2011","unstructured":"Mahady SE, Webster AC, Walker S, Sanyal A, George J (2011) The role of thiazolidinediones in non-alcoholic steatohepatitis\u2014a systematic review and meta analysis. J Hepatol 55(6):1383\u20131390","journal-title":"J Hepatol"},{"issue":"10","key":"1046_CR135","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2010.04467.x","volume":"32","author":"MO Rakoski","year":"2010","unstructured":"Rakoski MO, Singal AG, Rogers MA, Conjeevaram H (2010) Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 32(10):1211\u20131221","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1046_CR136","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","volume":"35","author":"E Boettcher","year":"2012","unstructured":"Boettcher E, Csako G, Pucino F, Wesley R, Loomba R (2012) Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 35(1):66\u201375","journal-title":"Aliment Pharmacol Ther"},{"issue":"36","key":"1046_CR137","doi-asserted-by":"crossref","first-page":"34268","DOI":"10.1074\/jbc.M300043200","volume":"278","author":"O Gavrilova","year":"2003","unstructured":"Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278(36):34268\u201334276","journal-title":"J Biol Chem"},{"issue":"4","key":"1046_CR138","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","volume":"46","author":"C Gluud","year":"2007","unstructured":"Gluud C, Brok J, Gong Y, Koretz RL (2007) Hepatology may have problems with putative surrogate outcome measures. J Hepatol 46(4):734\u2013742","journal-title":"J Hepatol"},{"issue":"1","key":"1046_CR139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1755-1536-5-1","volume":"5","author":"RA Hannivoort","year":"2012","unstructured":"Hannivoort RA, Hernandez-Gea V, Friedman SL (2012) Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogenesis Tissue Repair 5(1):1","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"1","key":"1046_CR140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.taap.2006.10.007","volume":"218","author":"MA Constantinou","year":"2007","unstructured":"Constantinou MA, Theocharis SE, Mikros E (2007) Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats. Toxicol Appl Pharmacol 218(1):11\u201319","journal-title":"Toxicol Appl Pharmacol"},{"issue":"20","key":"1046_CR141","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1161\/01.CIR.0000147614.85888.7A","volume":"110","author":"W Verreth","year":"2004","unstructured":"Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabiles N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P (2004) Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 110(20):3259\u20133269","journal-title":"Circulation"},{"issue":"11","key":"1046_CR142","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1007\/s00125-007-0782-1","volume":"50","author":"G Gastaldi","year":"2007","unstructured":"Gastaldi G, Russell A, Golay A, Giacobino JP, Habicht F, Barthassat V, Muzzin P, Bobbioni-Harsch E (2007) Upregulation of peroxisome proliferator-activated receptor gamma coactivator gene (PGC1A) during weight loss is related to insulin sensitivity but not to energy expenditure. Diabetologia 50(11):2348\u20132355","journal-title":"Diabetologia"},{"issue":"3","key":"1046_CR143","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/14740338.2011.534982","volume":"10","author":"KG Tolman","year":"2011","unstructured":"Tolman KG (2011) The safety of thiazolidinediones. Expert Opin Drug Saf 10(3):419\u2013428","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1046_CR144","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00125-010-1992-5","volume":"54","author":"E Blind","year":"2011","unstructured":"Blind E, Dunder K, de Graeff PA, Abadie E (2011) Rosiglitazone: a European regulatory perspective. Diabetologia 54(2):213\u2013218","journal-title":"Diabetologia"},{"issue":"16","key":"1046_CR145","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMp1010788","volume":"363","author":"J Woodcock","year":"2010","unstructured":"Woodcock J, Sharfstein JM, Hamburg M (2010) Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 363(16):1489\u20131491","journal-title":"N Engl J Med"},{"issue":"9","key":"1046_CR146","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1345\/aph.1E072","volume":"38","author":"TR Marcy","year":"2004","unstructured":"Marcy TR, Britton ML, Blevins SM (2004) Second-generation thiazolidinediones and hepatotoxicity. Ann Pharmacother 38(9):1419\u20131423","journal-title":"Ann Pharmacother"},{"issue":"4","key":"1046_CR147","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","volume":"34","author":"JD Lewis","year":"2011","unstructured":"Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34(4):916\u2013922","journal-title":"Diabetes Care"},{"issue":"6","key":"1046_CR148","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2337\/dc10-2412","volume":"34","author":"C Piccinni","year":"2011","unstructured":"Piccinni C, Motola D, Marchesini G, Poluzzi E (2011) Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 34(6):1369\u20131371","journal-title":"Diabetes Care"},{"issue":"24","key":"1046_CR149","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1158\/0008-5472.CAN-09-2067","volume":"69","author":"L Tian","year":"2009","unstructured":"Tian L, Zhou J, Casimiro MC, Liang B, Ojeifo JO, Wang M, Hyslop T, Wang C, Pestell RG (2009) Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis. Cancer Res 69(24):9236\u20139244","journal-title":"Cancer Res"},{"issue":"6","key":"1046_CR150","doi-asserted-by":"crossref","first-page":"E1195","DOI":"10.1152\/ajpendo.00513.2004","volume":"288","author":"SE Schadinger","year":"2005","unstructured":"Schadinger SE, Bucher NL, Schreiber BM, Farmer SR (2005) PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 288(6):E1195\u2013E1205","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"8","key":"1046_CR151","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/cr.2009.73","volume":"19","author":"H Wobser","year":"2009","unstructured":"Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Buttner R, Scholmerich J, Hellerbrand C (2009) Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res 19(8):996\u20131005","journal-title":"Cell Res"},{"issue":"17","key":"1046_CR152","doi-asserted-by":"crossref","first-page":"16927","DOI":"10.1074\/jbc.M309045200","volume":"279","author":"C Sharma","year":"2004","unstructured":"Sharma C, Pradeep A, Pestell RG, Rana B (2004) Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes. J Biol Chem 279(17):16927\u201316938","journal-title":"J Biol Chem"},{"issue":"7305","key":"1046_CR153","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","volume":"466","author":"JH Choi","year":"2010","unstructured":"Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Bluher M, Griffin PR, Spiegelman BM (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466(7305):451\u2013456","journal-title":"Nature"},{"issue":"7365","key":"1046_CR154","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","volume":"477","author":"JH Choi","year":"2011","unstructured":"Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He Y, Bruning JB, Marciano DP, Cameron MD, Laznik D, Jurczak MJ, Schurer SC, Vidovic D, Shulman GI, Spiegelman BM, Griffin PR (2011) Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477(7365):477\u2013481","journal-title":"Nature"},{"issue":"4","key":"1046_CR155","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0002-9440(10)63383-4","volume":"165","author":"H Steiling","year":"2004","unstructured":"Steiling H, Muhlbauer M, Bataille F, Scholmerich J, Werner S, Hellerbrand C (2004) Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease. Am J Pathol 165(4):1233\u20131241","journal-title":"Am J Pathol"},{"issue":"5","key":"1046_CR156","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.bbalip.2011.10.016","volume":"1821","author":"A Tailleux","year":"2012","unstructured":"Tailleux A, Wouters K, Staels B (2012) Roles of PPARs in NAFLD: Potential therapeutic targets. Biochim Biophys Acta 1821(5):809\u2013818","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"1046_CR157","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","volume":"39","author":"E Ip","year":"2004","unstructured":"Ip E, Farrell G, Hall P, Robertson G, Leclercq I (2004) Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39(5):1286\u20131296","journal-title":"Hepatology"},{"issue":"6","key":"1046_CR158","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1210\/en.2007-0014","volume":"148","author":"R Stienstra","year":"2007","unstructured":"Stienstra R, Mandard S, Patsouris D, Maass C, Kersten S, Muller M (2007) Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology 148(6):2753\u20132763","journal-title":"Endocrinology"},{"key":"1046_CR159","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-4419-1241-1_10","volume":"662","author":"K Kondo","year":"2010","unstructured":"Kondo K, Sugioka T, Tsukada K, Aizawa M, Takizawa M, Shimizu K, Morimoto M, Suematsu M, Goda N (2010) Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. Adv Exp Med Biol 662:77\u201382","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"1046_CR160","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3945\/jn.110.135210","volume":"141","author":"MA Abdelmegeed","year":"2011","unstructured":"Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ (2011) PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr 141(4):603\u2013610","journal-title":"J Nutr"},{"issue":"3","key":"1046_CR161","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","volume":"40","author":"C Fernandez-Miranda","year":"2008","unstructured":"Fernandez-Miranda C, Perez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA (2008) A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 40(3):200\u2013205","journal-title":"Dig Liver Dis"},{"issue":"1","key":"1046_CR162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2008.03.007","volume":"231","author":"P Thulin","year":"2008","unstructured":"Thulin P, Rafter I, Stockling K, Tomkiewicz C, Norjavaara E, Aggerbeck M, Hellmold H, Ehrenborg E, Andersson U, Cotgreave I, Glinghammar B (2008) PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicol Appl Pharmacol 231(1):1\u20139","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"1046_CR163","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.259","volume":"88","author":"P Sanwald-Ducray","year":"2010","unstructured":"Sanwald-Ducray P, Liogier D\u2019ardhuy X, Jamois C, Banken L (2010) Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study. Clin Pharmacol Ther 88(2):197\u2013203","journal-title":"Clin Pharmacol Ther"},{"key":"1046_CR164","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-2840-10-7","volume":"10","author":"BC Hansen","year":"2011","unstructured":"Hansen BC, Tigno XT, Benardeau A, Meyer M, Sebokova E, Mizrahi J (2011) Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor alpha\/gamma agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. Cardiovasc Diabetol 10:7","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1046_CR165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/0192623311429972","volume":"40","author":"P Lindblom","year":"2012","unstructured":"Lindblom P, Berg AL, Zhang H, Westerberg R, Tugwood J, Lundgren H, Marcusson-Stahl M, Sjogren N, Blomgren B, Ohman P, Skanberg I, Evans J, Hellmold H (2012) Tesaglitazar, a dual PPAR-alpha\/gamma agonist, hamster carcinogenicity, investigative animal and clinical studies. Toxicol Pathol 40(1):18\u201332","journal-title":"Toxicol Pathol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-012-1046-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-012-1046-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-012-1046-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T09:34:44Z","timestamp":1743413684000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-012-1046-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,15]]},"references-count":165,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1007\/s00018-012-1046-x","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,15]]}}}